Sujatha Venkataraman
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 16 | 2023 | 198 | 2.690 |
Why?
| Cerebellar Neoplasms | 12 | 2023 | 156 | 2.130 |
Why?
| Glioma | 11 | 2025 | 354 | 1.960 |
Why?
| Gene Expression Regulation, Neoplastic | 19 | 2025 | 1353 | 1.110 |
Why?
| Rhabdoid Tumor | 5 | 2025 | 97 | 0.980 |
Why?
| Superoxide Dismutase | 13 | 2016 | 328 | 0.970 |
Why?
| Cell Proliferation | 22 | 2025 | 2347 | 0.960 |
Why?
| Radiation Tolerance | 6 | 2022 | 97 | 0.900 |
Why?
| Nuclear Proteins | 6 | 2023 | 660 | 0.870 |
Why?
| Cell Line, Tumor | 26 | 2025 | 3184 | 0.820 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 47 | 0.770 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 580 | 0.710 |
Why?
| Antineoplastic Agents | 7 | 2022 | 2060 | 0.650 |
Why?
| Reactive Oxygen Species | 8 | 2022 | 579 | 0.650 |
Why?
| Teratoma | 4 | 2022 | 103 | 0.640 |
Why?
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 130 | 0.600 |
Why?
| Neoplastic Stem Cells | 3 | 2025 | 386 | 0.580 |
Why?
| Central Nervous System Neoplasms | 2 | 2023 | 148 | 0.510 |
Why?
| Brain Neoplasms | 6 | 2025 | 1164 | 0.500 |
Why?
| Apoptosis | 15 | 2024 | 2438 | 0.490 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 634 | 0.480 |
Why?
| Brain Stem Neoplasms | 3 | 2021 | 89 | 0.470 |
Why?
| MicroRNAs | 2 | 2012 | 677 | 0.470 |
Why?
| Superoxides | 5 | 2010 | 196 | 0.460 |
Why?
| Pyrazoles | 7 | 2022 | 405 | 0.450 |
Why?
| Cellular Senescence | 3 | 2019 | 174 | 0.430 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 430 | 0.420 |
Why?
| Cerebellum | 3 | 2012 | 217 | 0.400 |
Why?
| SMARCB1 Protein | 2 | 2025 | 29 | 0.390 |
Why?
| Tumor Cells, Cultured | 8 | 2020 | 930 | 0.380 |
Why?
| Repressor Proteins | 2 | 2012 | 400 | 0.350 |
Why?
| Prostatic Neoplasms | 3 | 2016 | 1013 | 0.350 |
Why?
| Histones | 4 | 2020 | 584 | 0.340 |
Why?
| RNA, Messenger | 5 | 2014 | 2676 | 0.340 |
Why?
| Transcription Factors | 3 | 2023 | 1632 | 0.340 |
Why?
| Aging | 1 | 2020 | 1772 | 0.340 |
Why?
| Intracellular Space | 1 | 2010 | 71 | 0.340 |
Why?
| Pyrimidines | 5 | 2017 | 445 | 0.330 |
Why?
| Cell Cycle | 9 | 2017 | 581 | 0.320 |
Why?
| Biomarkers, Tumor | 4 | 2020 | 1185 | 0.320 |
Why?
| Cell Survival | 7 | 2017 | 1077 | 0.310 |
Why?
| Mice | 16 | 2025 | 16644 | 0.290 |
Why?
| Ependymoma | 2 | 2020 | 176 | 0.270 |
Why?
| Humans | 55 | 2025 | 129126 | 0.260 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2016 | 257 | 0.250 |
Why?
| Pyrimidinones | 4 | 2020 | 102 | 0.250 |
Why?
| Neoplasm Recurrence, Local | 2 | 2022 | 963 | 0.250 |
Why?
| Sirtuin 2 | 1 | 2025 | 23 | 0.240 |
Why?
| Azepines | 3 | 2019 | 88 | 0.240 |
Why?
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 28 | 0.230 |
Why?
| Blotting, Western | 5 | 2014 | 1169 | 0.230 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2024 | 813 | 0.230 |
Why?
| NF-kappa B | 2 | 2019 | 652 | 0.230 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2016 | 757 | 0.230 |
Why?
| Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.230 |
Why?
| Animals | 18 | 2025 | 34600 | 0.220 |
Why?
| Radiation, Ionizing | 2 | 2022 | 75 | 0.220 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 326 | 0.220 |
Why?
| Radiation | 2 | 2021 | 24 | 0.220 |
Why?
| Hydrogen Peroxide | 7 | 2008 | 308 | 0.220 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 325 | 0.220 |
Why?
| DNA Repair | 2 | 2024 | 205 | 0.210 |
Why?
| Epigenomics | 2 | 2020 | 111 | 0.210 |
Why?
| Fever | 1 | 2004 | 301 | 0.210 |
Why?
| Genes, myc | 2 | 2020 | 50 | 0.200 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2012 | 39 | 0.200 |
Why?
| Chromatin | 3 | 2020 | 478 | 0.200 |
Why?
| von Willebrand Diseases | 1 | 2022 | 17 | 0.200 |
Why?
| Child | 14 | 2025 | 20805 | 0.200 |
Why?
| Molecular Targeted Therapy | 2 | 2016 | 387 | 0.200 |
Why?
| von Willebrand Factor | 1 | 2022 | 62 | 0.190 |
Why?
| Mutation | 3 | 2023 | 3700 | 0.190 |
Why?
| Cell Differentiation | 5 | 2025 | 1901 | 0.190 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 63 | 0.190 |
Why?
| Single-Cell Analysis | 2 | 2022 | 274 | 0.190 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.180 |
Why?
| Receptor, trkB | 1 | 2021 | 31 | 0.180 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 235 | 0.180 |
Why?
| Piperazines | 3 | 2022 | 337 | 0.180 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.170 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 215 | 0.170 |
Why?
| Mice, Nude | 3 | 2020 | 683 | 0.170 |
Why?
| Receptor, EphB4 | 1 | 2020 | 36 | 0.170 |
Why?
| Ephrin-B2 | 1 | 2020 | 50 | 0.170 |
Why?
| RNA, Small Interfering | 4 | 2022 | 571 | 0.170 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.170 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.170 |
Why?
| Astrocytoma | 1 | 2020 | 121 | 0.160 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 16 | 0.160 |
Why?
| Karyopherins | 1 | 2019 | 17 | 0.160 |
Why?
| Deoxycytidine | 1 | 2020 | 164 | 0.160 |
Why?
| Pteridines | 2 | 2016 | 22 | 0.160 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 466 | 0.150 |
Why?
| Sulfonamides | 1 | 2022 | 500 | 0.150 |
Why?
| Lysine | 1 | 2020 | 278 | 0.150 |
Why?
| Child, Preschool | 7 | 2021 | 10450 | 0.150 |
Why?
| Promoter Regions, Genetic | 5 | 2017 | 1200 | 0.150 |
Why?
| Enzyme Inhibitors | 4 | 2020 | 811 | 0.150 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 508 | 0.140 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 215 | 0.140 |
Why?
| Gene Expression Profiling | 3 | 2014 | 1689 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 68 | 0.140 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 12 | 0.140 |
Why?
| Cisplatin | 2 | 2016 | 298 | 0.140 |
Why?
| Phthalazines | 1 | 2017 | 40 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 125 | 0.140 |
Why?
| Triazoles | 2 | 2019 | 152 | 0.140 |
Why?
| Glioblastoma | 1 | 2020 | 322 | 0.140 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 31 | 0.130 |
Why?
| Radiation-Sensitizing Agents | 1 | 2016 | 40 | 0.130 |
Why?
| E1A-Associated p300 Protein | 1 | 2016 | 8 | 0.130 |
Why?
| Immunophenotyping | 1 | 2017 | 312 | 0.130 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 480 | 0.130 |
Why?
| Cell Movement | 3 | 2020 | 939 | 0.130 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2016 | 83 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 421 | 0.120 |
Why?
| Glutathione Peroxidase | 2 | 2006 | 41 | 0.120 |
Why?
| Metalloporphyrins | 1 | 2016 | 101 | 0.120 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 141 | 0.120 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 313 | 0.120 |
Why?
| Mitochondria | 3 | 2006 | 854 | 0.120 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 63 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 940 | 0.120 |
Why?
| Up-Regulation | 3 | 2016 | 828 | 0.110 |
Why?
| DNA Methylation | 3 | 2021 | 605 | 0.110 |
Why?
| Neural Stem Cells | 2 | 2012 | 142 | 0.110 |
Why?
| Survival Rate | 2 | 2020 | 1875 | 0.110 |
Why?
| Myocytes, Smooth Muscle | 2 | 2016 | 245 | 0.110 |
Why?
| Protein Processing, Post-Translational | 1 | 2016 | 450 | 0.110 |
Why?
| Prognosis | 3 | 2020 | 3788 | 0.100 |
Why?
| Cathepsin B | 1 | 2012 | 14 | 0.100 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.100 |
Why?
| Argonaute Proteins | 1 | 2012 | 28 | 0.100 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 41 | 0.100 |
Why?
| Aurora Kinases | 1 | 2012 | 29 | 0.100 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 140 | 0.100 |
Why?
| Early Growth Response Protein 1 | 1 | 2011 | 26 | 0.100 |
Why?
| Aurora Kinase A | 1 | 2012 | 55 | 0.100 |
Why?
| Xanthine Oxidase | 1 | 2011 | 78 | 0.090 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 163 | 0.090 |
Why?
| Dioxygenases | 1 | 2011 | 29 | 0.090 |
Why?
| Cyclin D1 | 2 | 2008 | 63 | 0.090 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 592 | 0.090 |
Why?
| CpG Islands | 1 | 2011 | 152 | 0.090 |
Why?
| Signal Transduction | 4 | 2012 | 4838 | 0.090 |
Why?
| Female | 14 | 2025 | 68517 | 0.080 |
Why?
| Neoplasm Grading | 2 | 2021 | 284 | 0.080 |
Why?
| Male | 11 | 2021 | 63201 | 0.080 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 485 | 0.080 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2021 | 195 | 0.080 |
Why?
| DNA-Binding Proteins | 2 | 2016 | 1423 | 0.080 |
Why?
| Brain | 3 | 2023 | 2628 | 0.080 |
Why?
| Neoplasm Proteins | 1 | 2012 | 421 | 0.080 |
Why?
| Carrier Proteins | 1 | 2012 | 732 | 0.080 |
Why?
| Tumor Stem Cell Assay | 2 | 2006 | 32 | 0.080 |
Why?
| Cell Hypoxia | 2 | 2008 | 229 | 0.080 |
Why?
| Quinazolines | 2 | 2022 | 243 | 0.070 |
Why?
| Free Radicals | 2 | 2006 | 104 | 0.070 |
Why?
| Down-Regulation | 1 | 2010 | 634 | 0.070 |
Why?
| Catalase | 2 | 2006 | 122 | 0.070 |
Why?
| Hypoxia | 2 | 2011 | 1035 | 0.070 |
Why?
| Transfection | 3 | 2019 | 896 | 0.070 |
Why?
| Dicumarol | 1 | 2006 | 2 | 0.070 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 169 | 0.070 |
Why?
| Energy Metabolism | 1 | 2012 | 836 | 0.070 |
Why?
| Transcription Factor AP-2 | 1 | 2006 | 83 | 0.070 |
Why?
| G2 Phase | 1 | 2006 | 36 | 0.070 |
Why?
| Base Sequence | 1 | 2010 | 2135 | 0.070 |
Why?
| Acetylcysteine | 1 | 2007 | 144 | 0.070 |
Why?
| Mouth Neoplasms | 1 | 2006 | 87 | 0.060 |
Why?
| Transcriptome | 2 | 2022 | 883 | 0.060 |
Why?
| Keratinocytes | 1 | 2006 | 243 | 0.060 |
Why?
| Hypertension, Pulmonary | 1 | 2016 | 1741 | 0.060 |
Why?
| Aconitate Hydratase | 1 | 2004 | 17 | 0.060 |
Why?
| Phosphorylation | 2 | 2020 | 1687 | 0.060 |
Why?
| DNA Damage | 2 | 2017 | 364 | 0.060 |
Why?
| Lipid Peroxidation | 1 | 2004 | 143 | 0.060 |
Why?
| Phenotype | 1 | 2012 | 3058 | 0.060 |
Why?
| Fatty Acids, Unsaturated | 1 | 2004 | 95 | 0.060 |
Why?
| Epigenesis, Genetic | 2 | 2020 | 616 | 0.060 |
Why?
| Membrane Potentials | 1 | 2004 | 260 | 0.060 |
Why?
| Ultraviolet Rays | 1 | 2006 | 384 | 0.050 |
Why?
| Androgens | 1 | 2005 | 174 | 0.050 |
Why?
| Carcinogenesis | 1 | 2025 | 209 | 0.050 |
Why?
| Cells, Cultured | 4 | 2016 | 4010 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 501 | 0.050 |
Why?
| Tyrosine | 1 | 2023 | 218 | 0.050 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 168 | 0.050 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 3 | 0.050 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.050 |
Why?
| Hot Temperature | 1 | 2004 | 364 | 0.050 |
Why?
| Spheroids, Cellular | 2 | 2012 | 73 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 48 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 97 | 0.050 |
Why?
| Transcriptional Activation | 2 | 2017 | 356 | 0.050 |
Why?
| Carcinoma, Squamous Cell | 1 | 2006 | 621 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 2 | 2017 | 1945 | 0.040 |
Why?
| RNA Polymerase II | 1 | 2024 | 317 | 0.040 |
Why?
| Oxidation-Reduction | 3 | 2011 | 1002 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 431 | 0.040 |
Why?
| Macrophages, Alveolar | 1 | 2004 | 380 | 0.040 |
Why?
| Hedgehog Proteins | 1 | 2022 | 187 | 0.040 |
Why?
| Fatal Outcome | 1 | 2021 | 301 | 0.040 |
Why?
| Biopsy | 1 | 2023 | 1086 | 0.040 |
Why?
| Immunotherapy, Adoptive | 1 | 2023 | 297 | 0.040 |
Why?
| Kinetics | 3 | 2008 | 1617 | 0.040 |
Why?
| Airway Resistance | 1 | 1999 | 38 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2006 | 878 | 0.040 |
Why?
| RNA Interference | 2 | 2012 | 441 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 703 | 0.040 |
Why?
| Cell Self Renewal | 1 | 2019 | 54 | 0.040 |
Why?
| Bone Morphogenetic Proteins | 1 | 2019 | 129 | 0.040 |
Why?
| Pneumonia | 1 | 2004 | 599 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2022 | 622 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2024 | 1403 | 0.040 |
Why?
| Time Factors | 2 | 2006 | 6518 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 58 | 0.040 |
Why?
| Oxidative Stress | 3 | 2011 | 1192 | 0.030 |
Why?
| Cohort Studies | 2 | 2021 | 5407 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 115 | 0.030 |
Why?
| Breast Neoplasms | 3 | 2006 | 2150 | 0.030 |
Why?
| Computer Simulation | 1 | 2021 | 941 | 0.030 |
Why?
| Benzamides | 1 | 2017 | 195 | 0.030 |
Why?
| Benzodiazepinones | 1 | 2016 | 16 | 0.030 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| Electron Spin Resonance Spectroscopy | 2 | 2007 | 90 | 0.030 |
Why?
| Enzyme Repression | 1 | 2016 | 6 | 0.030 |
Why?
| Urea | 1 | 2016 | 75 | 0.030 |
Why?
| Neoplasms | 1 | 2011 | 2475 | 0.030 |
Why?
| Radiation-Protective Agents | 1 | 2016 | 27 | 0.030 |
Why?
| Adolescent | 5 | 2021 | 20301 | 0.030 |
Why?
| Flow Cytometry | 2 | 2012 | 1142 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 119 | 0.030 |
Why?
| Acetylation | 1 | 2016 | 237 | 0.030 |
Why?
| Mitosis | 1 | 2016 | 178 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 346 | 0.030 |
Why?
| Respiratory Insufficiency | 1 | 1999 | 313 | 0.030 |
Why?
| Drug Synergism | 1 | 2016 | 358 | 0.030 |
Why?
| HeLa Cells | 1 | 2016 | 607 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2023 | 1924 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 656 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2020 | 2079 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2016 | 206 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 864 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2006 | 283 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 2016 | 417 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 616 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 773 | 0.030 |
Why?
| Young Adult | 2 | 2021 | 12389 | 0.030 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 133 | 0.030 |
Why?
| Colony-Forming Units Assay | 1 | 2012 | 90 | 0.030 |
Why?
| Fibroblasts | 2 | 2008 | 939 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 206 | 0.020 |
Why?
| Luciferases | 1 | 2012 | 148 | 0.020 |
Why?
| Gene Knockout Techniques | 1 | 2012 | 109 | 0.020 |
Why?
| Microarray Analysis | 1 | 2012 | 121 | 0.020 |
Why?
| Colorado | 1 | 2022 | 4396 | 0.020 |
Why?
| Genome, Human | 1 | 2014 | 392 | 0.020 |
Why?
| Cell Line | 2 | 2008 | 2737 | 0.020 |
Why?
| Embryo, Mammalian | 1 | 2012 | 226 | 0.020 |
Why?
| Tubulin | 1 | 2012 | 138 | 0.020 |
Why?
| Extracellular Space | 1 | 2011 | 120 | 0.020 |
Why?
| Metabolic Networks and Pathways | 1 | 2012 | 175 | 0.020 |
Why?
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2011 | 20 | 0.020 |
Why?
| Gene Expression | 1 | 2016 | 1462 | 0.020 |
Why?
| Adenosine | 1 | 2012 | 211 | 0.020 |
Why?
| Mammals | 1 | 2012 | 269 | 0.020 |
Why?
| Gene Silencing | 1 | 2011 | 185 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2011 | 303 | 0.020 |
Why?
| Animals, Newborn | 1 | 2011 | 805 | 0.020 |
Why?
| Cattle | 1 | 2011 | 962 | 0.020 |
Why?
| Pyridines | 1 | 2012 | 477 | 0.020 |
Why?
| Genomics | 1 | 2014 | 716 | 0.020 |
Why?
| Cyclin B1 | 1 | 2008 | 6 | 0.020 |
Why?
| Cyclin B | 1 | 2008 | 15 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2014 | 872 | 0.020 |
Why?
| Rats | 1 | 2016 | 5173 | 0.020 |
Why?
| Dicarbethoxydihydrocollidine | 1 | 2007 | 1 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1573 | 0.020 |
Why?
| Oxygen | 1 | 2012 | 902 | 0.020 |
Why?
| Breast | 1 | 2008 | 153 | 0.020 |
Why?
| G1 Phase | 1 | 2007 | 71 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2007 | 141 | 0.020 |
Why?
| Models, Molecular | 1 | 2012 | 1483 | 0.020 |
Why?
| Uncoupling Agents | 1 | 2006 | 1 | 0.020 |
Why?
| Glucose | 1 | 2012 | 983 | 0.020 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2006 | 31 | 0.020 |
Why?
| Glutathione Disulfide | 1 | 2006 | 31 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2006 | 140 | 0.020 |
Why?
| Bromodeoxyuridine | 1 | 2006 | 77 | 0.020 |
Why?
| Electron Transport | 1 | 2006 | 112 | 0.020 |
Why?
| Ceramides | 1 | 2006 | 104 | 0.020 |
Why?
| Adenoviruses, Human | 1 | 2005 | 26 | 0.020 |
Why?
| Pulmonary Artery | 1 | 2011 | 1030 | 0.020 |
Why?
| Chronic Disease | 1 | 2011 | 1707 | 0.020 |
Why?
| RNA | 1 | 2012 | 883 | 0.020 |
Why?
| Case-Control Studies | 1 | 2012 | 3342 | 0.010 |
Why?
| Glutathione | 1 | 2006 | 334 | 0.010 |
Why?
| Amitrole | 1 | 2004 | 9 | 0.010 |
Why?
| Asbestos | 1 | 2004 | 28 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2006 | 1284 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 269 | 0.010 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 313 | 0.010 |
Why?
| Antioxidants | 1 | 2005 | 543 | 0.010 |
Why?
| Epithelial Cells | 1 | 2008 | 1036 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2011 | 3953 | 0.010 |
Why?
| Monocytes | 1 | 2004 | 543 | 0.010 |
Why?
| Enzyme Activation | 1 | 2002 | 799 | 0.010 |
Why?
| Unconsciousness | 1 | 1999 | 19 | 0.010 |
Why?
| Lung Compliance | 1 | 1999 | 45 | 0.010 |
Why?
| Lung Diseases, Obstructive | 1 | 1999 | 44 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1192 | 0.010 |
Why?
| Adenocarcinoma | 1 | 2005 | 889 | 0.010 |
Why?
| Tidal Volume | 1 | 1999 | 83 | 0.010 |
Why?
| Adult | 2 | 2016 | 35512 | 0.010 |
Why?
| Positive-Pressure Respiration | 1 | 1999 | 75 | 0.010 |
Why?
| Nitric Oxide | 1 | 2002 | 886 | 0.010 |
Why?
| Intubation, Intratracheal | 1 | 1999 | 241 | 0.010 |
Why?
| Middle Aged | 1 | 2016 | 31079 | 0.010 |
Why?
| Lung Diseases, Interstitial | 1 | 1999 | 597 | 0.010 |
Why?
| Lung | 1 | 2004 | 3752 | 0.010 |
Why?
| Infant, Newborn | 1 | 1999 | 5739 | 0.000 |
Why?
| Infant | 1 | 1999 | 8992 | 0.000 |
Why?
|
|
Venkataraman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|